AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10926708
Drug: Oil-containing lotion
RxNorm normalized name: fish oil (containing omega-3 acids)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-containing lotion
Trial: 18821119
Drug: Control lotion
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control lotion
Trial: 8828530
Drug: Montelukast (MK-0476),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (MK-0476), 200 mg, three times daily for 10 1/3 days
Trial: 6377525
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl 100 micrograms in 8 ml normal saline
Trial: 6377525
Drug: Pethidine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 1.5 mg/kg 4-6-hourly as required
Trial: 29024718
Drug: Intraoperative incision
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative incision site injection
Trial: 22456780
Drug: MEB complexed
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEB complexed with chitin nano-crystals (topical emulsion and oral hard capsules)
Trial: 17885011
Drug: Cava (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cava (30 g ethanol/d for 28 days)
Trial: 15213052
Drug: Gin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gin (30 g ethanol/d for 28 days)
Trial: 15831802
Drug: Glu+Caf (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glu+Caf (48 g/h + 5 mg x kg(‐1) x h(‐1))
Trial: 15831802
Drug: Glu (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glu (48 g/h)
Trial: 7322717
Drug: Phenobarbital (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (daily for a mean of 35 months)
Trial: 28231822
Drug: Cilostazol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (50 mg) twice per day as an add-on therapy combined with AChEIs
Trial: 21068025
Drug: Escalated dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated dose weekly paclitaxel (80 mg/m² initially followed by 100 and 120 mg/m² unless severe toxicity is observed)
Trial: 21068025
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose weekly paclitaxel (80 mg/m²)
Trial: 17537155
Drug: Stress SPECT
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress SPECT with a low dose of TcTF (296 MBq)
Trial: 14966079
Drug: Prescription
RxNorm normalized name: Rx Prescription Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription
Trial: 11452245
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg oral clarithromycin twice daily for 4 days
Trial: 11452245
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg oral clarithromycin
Trial: 2915441
Drug: Intravenous prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prochlorperazine edisylate (10 mg)
Trial: 2915441
Drug: Placebo (2-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2-mL intravenous injection of sterile saline solution)
Trial: 1107772
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate (220 mg, three times a day for three weeks)
Trial: 9626923
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg itraconazole for 7 days
Trial: 21609915
Drug: Vasoactive agents
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive agents (Control)
Trial: 15900367
Drug: Human menopausal
RxNorm normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human menopausal gonadotropin (HMG) at a dose rate of 150 IU/day from day 3 of the cycle
Trial: 15900367
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone (GnRH) agonist at a dose rate of 800 microg/day by nasal spray or 500 microg/day subcutaneously in the mid-luteal phase, followed by standard HMG dose after pituitary down regulation
Trial: 15900367
Drug: Clomiphene at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene at a dose rate of 100 mg/day from day 3 and HMG from day 6
Trial: 9066739
Drug: Excision plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excision plus isolated hyperthermic limb perfusion (IHLP) using melphalan at 2 mg/kg body weight (n = 16)
Trial: 8350327
Drug: Intramuscular (im)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (im) gold plus 3 im injections of 120 mg methylprednisolone acetate
Trial: 8350327
Drug: Intramuscular (im)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (im) gold plus placebo
Trial: 3088664
Drug: Fluvoxamine 50
RxNorm normalized name: fluvoxamine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 50 mg twice a day
Trial: 3088664
Drug: Mianserin 20
RxNorm normalized name: mianserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 20 mg twice a day
Trial: 27315415
Drug: Problem solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem solving program delivered by physical and occupational therapy practitioners, including a structured interview and an education and resource packet.
Trial: 23219490
Drug: Pay Attention!
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pay Attention! intervention (16 bi-weekly sessions)
Trial: 20861424
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mg/mL at 2 mL/h for 24 hours
Trial: 20861424
Drug: Saline at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline at 2 mL/h for 24 hours
Trial: 16372192
Drug: Local intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Local intra-arterial fibrinolysis (maximum of 50 mg rtPA injected into the ophthalmic artery)
Trial: 16372192
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (bulbus massage, topical beta-blocker, acetazolamide, acetylsalicylic acid, heparin, isovolemic hemodilution)
Trial: 10899723
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg clarithromycin (CLA)
Trial: 10899723
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg clarithromycin (CLA)
Trial: 10899723
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg clarithromycin (CLA)
Trial: 10899723
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg clarithromycin (CLA)
Trial: 8646825
Drug: Talinolol oral
RxNorm normalized name: talinolol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talinolol oral bioavailability.
Trial: 30030269
Drug: FR +
RxNorm normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FR + L (fludarabine plus rituximab plus lenalidomide consolidation)
Trial: 22201185
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with tidal volume (VT) of 8 or 6 ml kg(‐1) for TLV and OLV, respectively.
Trial: 10877166
Drug: 2-day cefixime
RxNorm normalized name: (-)-cefixim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-day cefixime (8 mg/kg/day given once daily followed by 3 days of placebo)
Trial: 8415813
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose prostaglandin E1 (PGE1) infusion (0.02 microgram kg‐1 min‐1)
Trial: 3534859
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 to 50 mg b.i.d.)
Trial: 3534859
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of frusemide (25 to 100 mg o.d.)
Trial: 23477160
Drug: Compound Xiatianwu
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Xiatianwu combined with methotrexate (MTX)
Trial: 23477160
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Compound Xiatianwu + MTX and MTX)
Trial: 19930776
Drug: Daily mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mometasone furoate nasal spray for six weeks
Trial: 19930776
Drug: Self-adjusted regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-adjusted regimen of mometasone furoate nasal spray (daily for one week, every alternate day for one week, then self-adjusted for four weeks)
Trial: 19930776
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (daily and self-adjusted)
Trial: 28639987
Drug: Antithrombotic therapies
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapies
Trial: 8627643
Drug: Bolus 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus 5-FU at 500 mg/m2 for 5 days followed in 2 weeks by weekly bolus 5-FU at 600 mg/m2 (Treatment A)
Trial: 8627643
Drug: 5-FU at
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU at 300 mg/m2 per day by continuous infusion (Treatment C)
Trial: 8627643
Drug: 5-FU at
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU at 300 mg/m2 per day by continuous infusion plus weekly cisplatin at 20 mg/m2 (Treatment D)
Trial: 8627643
Drug: Bolus 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus 5-FU at 500 mg/m2 for 5 days followed in 2 weeks by weekly bolus 5-FU at 600 mg/m2 plus weekly cisplatin at 20 mg/m2 (Treatment B)
Trial: 6362905
Drug: 0.3 mg/day
RxNorm normalized name: cloNIDine HCl 0.3 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/day clonidine for 3 days
Trial: 6362905
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg iv naloxone
Trial: 6362905
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with naloxone
Trial: 6362905
Drug: Clonidine treatment
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine treatment with naloxone
Trial: 26852904
Drug: GLPG0974 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG0974 (single doses up to 250 mg)
Trial: 26852904
Drug: GLPG0974 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG0974 (multiple daily doses up to 400 mg for 14 days)
Trial: 20414532
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of salt/day for 7 days (Phase 1)
Trial: 20414532
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of salt/day (subgroup 1, Phase 2)
Trial: 20414532
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of salt/day (subgroup II, Phase 2)
Trial: 14617582
Drug: Edrophonium (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium (0.5 mg x kg(‐1))
Trial: 10745385
Drug: Albendazole 600
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 600 mg every six months
Trial: 8955968
Drug: Mixed group
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed group (mepivacaine 1% with 0.1 mg fentanyl)
Trial: 22374468
Drug: Nizatidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (150 mg)
Trial: 16429411
Drug: Bilateral continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral continuous intraputamenal infusion of liatermin 15 microg/putamen/day
Trial: 7955745
Drug: Supine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supine and upright radionuclide esophageal transit (RET) before treatment
Trial: 31328871
Drug: Human umbilical
RxNorm normalized name: Human umbilical tissue derived cells
DrugBank: Human umbilical tissue derived cells (DB17907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human umbilical cord blood-derived mesenchymal stem cell (hUCBMSC)-conditioned media containing cream with serum
Trial: 31328871
Drug: Human umbilical
RxNorm normalized name: Human umbilical tissue derived cells
DrugBank: Human umbilical tissue derived cells (DB17907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human umbilical cord blood-derived mesenchymal stem cell (hUCBMSC)-conditioned media containing cream without serum
Trial: 29482586
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted internet-delivered cognitive behavioural therapy (iCBT) Space from Depression, consisting of 7 weekly modules with post-session feedback support.
Trial: 29482586
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control group (no active treatment).
Trial: 26658227
Drug: DPYD c.1129-5923
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPYD c.1129-5923 C>G and hapB3 variants
Trial: 26658227
Drug: DPYD c.1129-5923
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPYD c.1129-5923 C>G/hapB3
Trial: 23833846
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl with 0.1 mg morphine
Trial: 20666786
Drug: 8 mm,
RxNorm normalized name: Steri-Tamp Seal, 28 mm, blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mm, v4.1 mm Straumann Standard Plus tissue-level implants (Group A)
Trial: 20666786
Drug: 10 mm,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mm, v4.1 mm Straumann Standard Plus tissue-level implants (Group B)
Trial: 14744403
Drug: Therapeutic options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic options for hand dermatitis, including treatments for recalcitrant cases.
Trial: 10839658
Drug: Fozivudine tidoxil
RxNorm normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fozivudine tidoxil (FZD) 200 mg daily
Trial: 10839658
Drug: Fozivudine tidoxil
RxNorm normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fozivudine tidoxil (FZD) 400 mg daily
Trial: 10839658
Drug: Fozivudine tidoxil
RxNorm normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fozivudine tidoxil (FZD) 200 mg twice daily
Trial: 10839658
Drug: Fozivudine tidoxil
RxNorm normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fozivudine tidoxil (FZD) 800 mg daily
Trial: 10839658
Drug: Fozivudine tidoxil
RxNorm normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fozivudine tidoxil (FZD) 400 mg twice daily
Trial: 10839658
Drug: Fozivudine tidoxil
RxNorm normalized name: Fozivudine Tidoxil
DrugBank: Fozivudine Tidoxil (DB12423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fozivudine tidoxil (FZD) 600 mg twice daily
Trial: 8977752
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin 0.2 IU/kg
Trial: 8977752
Drug: Intravenous arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous arginine 20 g/m2
Trial: 8977752
Drug: Intramuscular glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular glucagon 1 mg
Trial: 8977752
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 100 micrograms
Trial: 8977752
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 200 micrograms
Trial: 1487621
Drug: Lorazepam 1
RxNorm normalized name: lorazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 1 mg (positive internal control)
Trial: 1487621
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg with alcohol (0.6 g/kg)
Trial: 1487621
Drug: Lorazepam 1
RxNorm normalized name: lorazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 1 mg with alcohol (0.6 g/kg)
Trial: 26942445
Drug: Intragastric glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intragastric glucose loads of 10 g, 25 g, and 75 g glucose dissolved in 300 ml tap water.
Trial: 24481874
Drug: Evolocumab (subcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (subcutaneous, administered every 2 weeks or every month for 12 weeks)
Trial: 20104762
Drug: Wenxinkeli (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wenxinkeli (5 g, 3 times a day with warm water) for 4 weeks
Trial: 20104762
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (adenosine triphosphate, coenzyme A, vitamin C, coenzyme Q10 and other nutrients cardiac drugs) for 4 weeks
Trial: 14977792
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion at 100 microg/min for 2 min, then titrated to maintain SBP at 100% of baseline.
Trial: 14977792
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion at 90% of baseline SBP.
Trial: 14977792
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion at 80% of baseline SBP.
Trial: 14977792
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion at 100% of baseline SBP.
Trial: 11686426
Drug: Cefprozil, 500
RxNorm normalized name: Cefprozil, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil, 500 mg twice daily for 5 days
Trial: 11686426
Drug: Clarithromycin, 500
RxNorm normalized name: Clarithromycin, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, 500 mg twice daily for 10 days
Trial: 9784725
Drug: Enterosorbent polysorb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enterosorbent polysorb and a complex of antioxidants (tocoferolum acetatum, ascorbic acid, quercetin) as a supplement to conventional therapy (Group I, n = 76)
Trial: 9784725
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy only (Group II, n = 67)
Trial: 3280363
Drug: Domiodol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domiodol (0.5 mg/kg three times daily for 14 days)
Trial: 11397997
Drug: Oral maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral maintenance treatment with ritodrine
Trial: 11397997
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of β-sympathomimetics
Trial: 11397997
Drug: Prolonged treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged treatment by β-sympathomimetics
Trial: 22607850
Drug: aCRT (adaptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aCRT (adaptive cardiac resynchronization therapy)
Trial: 17509304
Drug: Premarin 1.25
RxNorm normalized name: Premarin 1.25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin 1.25 mg 3 times daily
Trial: 17509304
Drug: Premarin 1.25
RxNorm normalized name: Premarin 1.25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin 1.25 mg once daily
Trial: 17509304
Drug: Premarin 1.25
RxNorm normalized name: Premarin 1.25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin 1.25 mg 3 times daily and warfarin 1 mg
Trial: 17509304
Drug: Premarin 1.25
RxNorm normalized name: Premarin 1.25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin 1.25 mg once daily and warfarin 1 mg
Trial: 16027621
Drug: Fränkel appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fränkel appliance therapy
Trial: 12458696
Drug: Massage therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy, 20-minute sessions, twice a week for five weeks
Trial: 12458696
Drug: Relaxation therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy, 20-minute sessions, twice a week for five weeks